Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2020-03-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well abiraterone acetate works in treating patients with
hormone-resistant prostate cancer that has spread from the primary site (place where it
started) to other places in the body (metastatic). Abiraterone acetate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.